A Neukamm1,2, A D Høiseth1,2, G Einvik2,3, S Lehmann4,5, T-A Hagve2,6, V Søyseth2,3, T Omland1,2. 1. Department of Cardiology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway. 2. Center for Heart Failure Research and KG Jebsen Cardiac Research Centre, University of Oslo, Oslo, Norway. 3. Department of Pulmonology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway. 4. Department of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway. 5. Section for Thoracic Medicine, Department of Clinical Science, University of Bergen, Bergen, Norway. 6. Unit of Medical Biochemistry, Division of Diagnostics and Technology, Akershus University Hospital, Lørenskog, Norway.
Abstract
OBJECTIVES: The objective of this study was to examine whether statin therapy is associated with enhanced endothelium-dependent vascular function, improved pulmonary function and reduced systemic inflammation in patients with chronic obstructive pulmonary disease (COPD). DESIGN AND SETTING: This randomized, placebo-controlled, double-blind, parallel trial including patients with COPD was performed at two University hospitals in Norway. SUBJECTS, INTERVENTION AND MEASUREMENTS: Patients with stable COPD (n = 99) were assigned randomly to receive rosuvastatin 10 mg (n = 49) or matching placebo (n = 50) once daily for 12 weeks. The primary outcome measure was change in endothelium-dependent vascular function measured using peripheral arterial tonometry and expressed as the reactive hyperaemia index. Secondary end-points were change in pulmonary function, as assessed by forced expiratory volume in 1 s (FEV1) and FEV1/forced vital capacity (FVC), and change in the circulating levels of the inflammatory markers interleukin-6 (IL6) and high-sensitivity C-reactive protein (hsCRP). RESULTS: In the overall study population, no significant between-group difference in change in endothelium-dependent vascular or pulmonary function was observed. Rosuvastatin therapy was associated with a reduction in hsCRP (-20% vs. 11%, P = 0.017) and an attenuation of the rise in IL6 concentration (8% vs. 30%, P = 0.028) compared with placebo. In a prespecified subgroup analysis of patients with a supra-median circulating hsCRP concentration (>1.7 mg L(-1) ), rosuvastatin was associated with improved endothelium-dependent vascular function (13% vs. 2%, P = 0.026). CONCLUSIONS: In stable COPD patients without the standard indications for statin therapy, rosuvastatin treatment is associated with a significant attenuation of systemic inflammation and improvement in endothelial-dependent vascular function in patients with evidence of systemic inflammation.
RCT Entities:
OBJECTIVES: The objective of this study was to examine whether statin therapy is associated with enhanced endothelium-dependent vascular function, improved pulmonary function and reduced systemic inflammation in patients with chronic obstructive pulmonary disease (COPD). DESIGN AND SETTING: This randomized, placebo-controlled, double-blind, parallel trial including patients with COPD was performed at two University hospitals in Norway. SUBJECTS, INTERVENTION AND MEASUREMENTS: Patients with stable COPD (n = 99) were assigned randomly to receive rosuvastatin 10 mg (n = 49) or matching placebo (n = 50) once daily for 12 weeks. The primary outcome measure was change in endothelium-dependent vascular function measured using peripheral arterial tonometry and expressed as the reactive hyperaemia index. Secondary end-points were change in pulmonary function, as assessed by forced expiratory volume in 1 s (FEV1) and FEV1/forced vital capacity (FVC), and change in the circulating levels of the inflammatory markers interleukin-6 (IL6) and high-sensitivity C-reactive protein (hsCRP). RESULTS: In the overall study population, no significant between-group difference in change in endothelium-dependent vascular or pulmonary function was observed. Rosuvastatin therapy was associated with a reduction in hsCRP (-20% vs. 11%, P = 0.017) and an attenuation of the rise in IL6 concentration (8% vs. 30%, P = 0.028) compared with placebo. In a prespecified subgroup analysis of patients with a supra-median circulating hsCRP concentration (>1.7 mg L(-1) ), rosuvastatin was associated with improved endothelium-dependent vascular function (13% vs. 2%, P = 0.026). CONCLUSIONS: In stable COPDpatients without the standard indications for statin therapy, rosuvastatin treatment is associated with a significant attenuation of systemic inflammation and improvement in endothelial-dependent vascular function in patients with evidence of systemic inflammation.
Authors: Alison Morris; Meghan Fitzpatrick; Marnie Bertolet; Shulin Qin; Lawrence Kingsley; Nicolas Leo; Cathy Kessinger; Heather Michael; Deborah Mcmahon; Renee Weinman; Stephen Stone; Joseph K Leader; Eric Kleerup; Laurence Huang; Stephen R Wisniewski Journal: AIDS Date: 2017-02-20 Impact factor: 4.177
Authors: Georgia M Walton; James A Stockley; Diane Griffiths; Charandeep S Sadhra; Thomas Purvis; Elizabeth Sapey Journal: J Clin Med Date: 2016-10-11 Impact factor: 4.241
Authors: Anke Neukamm; Gunnar Einvik; Arne Didrik Høiseth; Vidar Søyseth; Nils Henrik Holmedahl; Natalia Kononova; Torbjørn Omland Journal: BMC Pulm Med Date: 2016-11-25 Impact factor: 3.317
Authors: Jonathan T Davies; Spencer F Delfino; Chad E Feinberg; Meghan F Johnson; Veronica L Nappi; Joshua T Olinger; Anthony P Schwab; Hollie I Swanson Journal: Lipid Insights Date: 2016-11-14